IHC and DSP analysis of cervical and head and neck tumour progression

• Research type

  Research Study

• Full title

  Validation of antigen expression in cervical and head and neck cancers by immunohistochemistry analysis and Digital Spatial Profiling.

• IRAS ID

  331903

• Contact name

  Gayle Marshall

• Contact email

  gayle.marshall@md.catapult.org.uk

• Sponsor organisation

  pHion Therapeutics

• Duration of Study in the UK

  0 years, 11 months, 31 days

• Research summary

  MDC will be working with UK-based vaccine development company, pHion Therapeutics (pHion), to investigate antigen expression in cervical and head and neck cancers. The antigens of interest are HPV16 E1, E6, E7 and MAGEA4 which will be assessed using commercially available Tissue Microarrays (TMAs). The aim of the project is to correlate antigen expression with patient survival, metastasis and HPV status (if data is available). The outputs of this project will inform decision making about pHion vaccine targets and contribute to pHion's drug development objectives.

• REC name

  Yorkshire & The Humber - South Yorkshire Research Ethics Committee

• REC reference

  23/YH/0183

• Date of REC Opinion

  21 Aug 2023

• REC opinion

  Further Information Favourable Opinion